JP2022549172A5 - - Google Patents

Info

Publication number
JP2022549172A5
JP2022549172A5 JP2022517452A JP2022517452A JP2022549172A5 JP 2022549172 A5 JP2022549172 A5 JP 2022549172A5 JP 2022517452 A JP2022517452 A JP 2022517452A JP 2022517452 A JP2022517452 A JP 2022517452A JP 2022549172 A5 JP2022549172 A5 JP 2022549172A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549172A (ja
Filing date
Publication date
Priority claimed from CN201910882351.2A external-priority patent/CN112521501A/zh
Application filed filed Critical
Publication of JP2022549172A publication Critical patent/JP2022549172A/ja
Publication of JP2022549172A5 publication Critical patent/JP2022549172A5/ja
Priority to JP2025112231A priority Critical patent/JP2025165930A/ja
Pending legal-status Critical Current

Links

JP2022517452A 2019-09-18 2020-09-16 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途 Pending JP2022549172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112231A JP2025165930A (ja) 2019-09-18 2025-07-02 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910882351.2 2019-09-18
CN201910882351.2A CN112521501A (zh) 2019-09-18 2019-09-18 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
PCT/CN2020/115483 WO2021052349A1 (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112231A Division JP2025165930A (ja) 2019-09-18 2025-07-02 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途

Publications (2)

Publication Number Publication Date
JP2022549172A JP2022549172A (ja) 2022-11-24
JP2022549172A5 true JP2022549172A5 (https=) 2023-09-27

Family

ID=74883118

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517452A Pending JP2022549172A (ja) 2019-09-18 2020-09-16 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途
JP2025112231A Pending JP2025165930A (ja) 2019-09-18 2025-07-02 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112231A Pending JP2025165930A (ja) 2019-09-18 2025-07-02 Ｇｉｐｒ抗体及びｇｌｐ－１とのその融合タンパク質、並びにその医薬組成物及び用途

Country Status (10)

Country Link
US (1) US20220411520A1 (https=)
EP (1) EP4063385A4 (https=)
JP (2) JP2022549172A (https=)
KR (1) KR20220063221A (https=)
CN (4) CN112521501A (https=)
AU (1) AU2020350715A1 (https=)
CA (1) CA3154756A1 (https=)
MX (1) MX2022003251A (https=)
TW (1) TWI889705B (https=)
WO (1) WO2021052349A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022291264A1 (en) * 2021-06-09 2023-12-14 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
CN119744271A (zh) * 2022-09-08 2025-04-01 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
CN120019167A (zh) * 2022-10-12 2025-05-16 首尔大学医院 利用gipr标记物的用于预测磺酰脲类依赖性的组合物及其预测方法
EP4613768A1 (en) * 2022-11-02 2025-09-10 Suzhou Alphamab Co., Ltd Gipr binding protein and use thereof
WO2025092705A1 (zh) * 2023-10-31 2025-05-08 山东博安生物技术股份有限公司 Gipr阻断型抗体及其抗体偶联物
WO2025237353A1 (zh) * 2024-05-15 2025-11-20 信立泰(成都)生物技术有限公司 一种抗gipr抗体或其抗原结合片段及用途
WO2025252023A1 (en) * 2024-06-03 2025-12-11 Fortvita Biologics Inc. Modulators for gipr, glp1r and/or gcgr and uses thereof
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁（杭州）生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
ATE251465T1 (de) 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
BR112014013925B1 (pt) * 2011-12-12 2022-02-22 Receptos Llc Compostos moduladores do receptor de glp-1 e composição e combinação farmacêutica compreendendo os ditos compostos
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
IL313587A (en) * 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
EA201992502A1 (ru) * 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (en) * 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
CN117126279A (zh) * 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Similar Documents

Publication Publication Date Title
JP2022549172A5 (https=)
US11566071B2 (en) Nucleic acid molecules encoding anti-GPRC5D antibodies
JP2024150751A5 (https=)
JP2020180158A5 (https=)
JP2021518132A5 (https=)
JP2020508655A5 (https=)
JP2020501531A5 (https=)
JP2020536532A5 (https=)
CN116063508A (zh) 靶向Fc受体样5的抗体及使用方法
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
US11851460B2 (en) PD1 binding agents
JP2022553922A5 (https=)
JP2018522888A5 (https=)
JP2018510617A5 (https=)
JP2020502233A5 (https=)
JP2021511387A5 (https=)
CN118076387A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
JP2020513759A5 (https=)
RU2019140933A (ru) Средства, пути применения и способы лечения
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
JP2022540918A5 (https=)
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
JP2022500382A5 (https=)
JP2021518748A5 (https=)
JP2025130076A5 (https=)